Patients were randomly assigned ( 1:1 ) to receive trabectedin 1.5 mg/m2 24-h intravenous ( i.v. ) infusion every 3 weeks ( q3wk ) ( Arm A ) , or doxorubicin 75 mg/m2 i.v. , q3wk , or doxorubicin 60 mg/m2 i.v. plus ifosfamide ( range , 6-9 g/m2 ) i.v. q3wk ( Arm B ) .